Repligen Cash Flow Statement
RGEN / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
Repligen generated $117M in operating cash flow and $94M in free cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Negative profit margin: -18.1%
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $48.9M | -$25.5M | $35.6M | $186.0M | $128.3M | $59.9M | $21.4M | $16.6M | $28.4M | $11.7M | $16.1M | $8.2M | $16.1M | $14.2M | -$1.6M |
| Depreciation & Amortization | $78.7M | $69.7M | $68.6M | $51.0M | $38.4M | $27.1M | $20.9M | $15.8M | $10.5M | $5.3M | $3.1M | $4.0M | $3.1M | $3.5M | $1.3M |
| Operating Cash Flow | $117.4M | $175.4M | $113.9M | $172.1M | $119.0M | $62.6M | $67.2M | $32.8M | $17.5M | $7.5M | $25.9M | $18.4M | $25.9M | $13.4M | $2.3M |
| Capital Expenditures | $23.5M | $25.7M | $36.2M | $84.8M | $67.1M | $22.5M | $18.5M | $10.6M | $5.5M | $4.3M | $4.6M | $5.6M | $4.6M | $1.3M | $575.5K |
| Free Cash Flow | $93.9M | $149.7M | $77.7M | $87.2M | $51.9M | $40.2M | $48.7M | $22.1M | $12.0M | $3.2M | $21.3M | $12.8M | $21.3M | $12.2M | $1.7M |
| Share Buybacks | $0 | $0 | $14.4M | $0 | $0 | - | - | - | - | - | - | - | - | - | $330.9K |
| FCF Margin | - | - | - | - | - | - | - | - | 39.2% | 3.1% | 31.2% | 20.1% | 31.2% | 19.6% | 7.4% |